Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon May 26, 2023 9:06pm
391 Views
Post# 35466842

Let me understand??

Let me understand??We had a decent run up, on the Q1 meeting statements. Price went from ( CDN $ ) low about;$1.60 to a high of $3.00, within a month. Within in that a run of 5 up- days, in & around 8% to 12%/ day. People were all giddy. News came out. Complicated yes. Not a buy- out or partnership. They did however indicate they would be expeditiously advance to phase 3. With both MBc treatment & Pancreatic cancer treatment. So, all good news, with more details to come in a week. The price dropped 16% to 20% depending on which numbers are used. Now! The sky is falling. Everything up to now doom & gloom etc etc. The on- going development of Pela to phase 3 has advanced. The price fell. No connection what so ever. Yes, they need a partner. Reality? The door is wide open. Roche does seem to have the lead. All, said. My gut feeling. There will not be a partnership. There will be a complete buy- out. You see folks. Pfizer does not own Taxol. BMS does have a cancer delivery patent for taxol. Roche can come in & benefit from both MBc Pela combo & their Pancreatic combo. The whole picture now makes sense. Get the Panc results, negotiate a buyout. BTW, I could be wrong about the Taxol ownership. The pharma world is cryptic at best.
<< Previous
Bullboard Posts
Next >>